SILAC in Biomarker Discovery

  • Benjamin C. Orsburn
Part of the Methods in Molecular Biology book series (MIMB, volume 1002)


Stable isotope labeling with amino acids in cell culture (SILAC) has become an extremely valuable tool in quantitative proteomics and in biomarker discovery. Incorporation of SILAC labels occurs when cells are passaged multiple times in media where the endogenous amino acids are replaced with the heavy isotope ones. During a typical experiment, cells from heavy and light strains are combined in equal ratios and all steps of protein extraction and digestion occur on these cells together, minimizing the number of external variables introduced during sample processing. Potential biomarkers are revealed during liquid chromatography-tandem mass spectrometry analysis by peptides that differ considerably in intensity between the two strains as revealed by the mass shift from the incorporated SILAC label. The protocol presented here describes how to perform a typical experiment using the SILAC technology for the search for biomarkers as revealed by differences in protein expression levels, as well as by phosphorylation, a common posttranslational modification.

Key words

SILAC Biomarkers Phosphoproteomics Phosphopeptide FASP FACE TiO2 IMAC 


  1. 1.
    Mann M (2006) Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 7:952–958PubMedCrossRefGoogle Scholar
  2. 2.
    Cuomo A, Moretti S, Minucci S, Bonaldi T (2011) SILAC-based proteomic analysis to dissect the “histone modification signature” of human breast cancer cells. Amino Acids 41:387–399PubMedCrossRefGoogle Scholar
  3. 3.
    Everley PA, Krijgsveld J, Zetter BR, Gygi SP (2004) Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics 3:729–735PubMedCrossRefGoogle Scholar
  4. 4.
    Matta A, Ralhan R, DeSouza LV, Siu KW (2010) Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery. Mass Spectrom Rev 29:945–961PubMedCrossRefGoogle Scholar
  5. 5.
    Gronborg M, Kristiansen TZ, Iwahori A et al (2006) Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5:157–171PubMedGoogle Scholar
  6. 6.
    Lee HJ, Na K, Kwon MS, Kim H, Kim KS, Paik YK (2009) Quantitative analysis of phosphopeptides in search of the disease biomarker from the hepatocellular carcinoma specimen. Proteomics 9:3395–3408PubMedCrossRefGoogle Scholar
  7. 7.
    Orsburn BC (2011) The handy little book of proteomics protocols. BTB, Baltimore, MDGoogle Scholar
  8. 8.
    Orsburn BC, Stockwin LH, Newton DL (2011) Challenges in plasma membrane phosphoproteomics. Expert Rev Proteomics 8:483–494PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Benjamin C. Orsburn
    • 1
  1. 1.LMIV Molecular Pathogenesis and BiomerkersRockvilleUSA

Personalised recommendations